# BX-1 in Spasticity Due to Multiple Sclerosis

> **NCT03756974** · PHASE3 · COMPLETED · sponsor: **Bionorica SE** · enrollment: 397 (actual)

## Conditions studied

- Spasticity Due to Multiple Sclerosis

## Interventions

- **DRUG:** BX-1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03756974
- **Lead sponsor:** Bionorica SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-18
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 397 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03756974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03756974, "BX-1 in Spasticity Due to Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03756974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*